Clinical Trial Update: A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the biological effects of Saruparib (AZD5305), darolutamide, and their combination in men with newly diagnosed prostate cancer; recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Nubeqa (darolutamide)
• Saruparib (saruparib)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 1 | Status: RECRUITING